Insulin Aspart; Insulin Degludec Patent Expiration
Insulin Aspart; Insulin Degludec is used for managing glycemic control in patients with diabetes mellitus. It was first introduced by Novo Nordisk Inc
Insulin Aspart; Insulin Degludec Patents
Given below is the list of patents protecting Insulin Aspart; Insulin Degludec, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ryzodeg 70/30 | US9884094 | Method of treating diabetes mellitus | May 01, 2033 | Novo |
| Ryzodeg 70/30 | US9132239 | Dial-down mechanism for wind-up pen | Feb 01, 2032 | Novo |
| Ryzodeg 70/30 | US7615532 | Insulin derivatives | Jun 28, 2029 | Novo |
| Ryzodeg 70/30 | US9457154 | Injection device with an end of dose feedback mechanism | Sep 27, 2027 | Novo |
| Ryzodeg 70/30 | US9687611 | Injection device with torsion spring and rotatable display | Feb 27, 2027 | Novo |
| Ryzodeg 70/30 | US7686786 | Dial-down mechanism for wind-up pen | Aug 03, 2026 | Novo |
| Ryzodeg 70/30 | USRE46363 | Dial-down mechanism for wind-up pen | Aug 03, 2026 | Novo |
| Ryzodeg 70/30 | US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism | Jul 17, 2026 | Novo |
| Ryzodeg 70/30 | US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jul 17, 2026 | Novo |
| Ryzodeg 70/30 | US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jul 17, 2026 | Novo |
| Ryzodeg 70/30 | US10357616 | Injection device with an end of dose feedback mechanism | Jan 20, 2026 | Novo |
| Ryzodeg 70/30 | US10376652 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ryzodeg 70/30 | US9108002 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ryzodeg 70/30 | US9616180 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ryzodeg 70/30 | US9861757 | Injection device with an end of dose feedback mechanism | Jan 20, 2026 | Novo |
| Ryzodeg 70/30 | US8684969 | Injection device with torsion spring and rotatable display | Oct 20, 2025 | Novo |
| Ryzodeg 70/30 | US7762994 | Needle mounting system and a method for mounting a needle assembly |
May 23, 2024
(Expired) | Novo |
| Ryzodeg 70/30 | US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun 30, 2023
(Expired) | Novo |
| Ryzodeg 70/30 | US6899699 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Ryzodeg 70/30 | US8672898 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Ryzodeg 70/30 | US9486588 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Ryzodeg 70/30 | US5866538 | Insulin preparations containing NaCl |
Jun 20, 2017
(Expired) | Novo |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Aspart; Insulin Degludec's patents.
Latest Legal Activities on Insulin Aspart; Insulin Degludec's Patents
Given below is the list recent legal activities going on the following patents of Insulin Aspart; Insulin Degludec.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jul, 2021 | US9884094 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2021 | US7615532 |
| Patent Term Extension Certificate Critical | 11 Sep, 2018 | US7615532 |
| Notice of Final Determination -Eligible | 14 Mar, 2018 | US7615532 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Feb, 2018 | US9884094 |
| Recordation of Patent Grant Mailed Critical | 06 Feb, 2018 | US9884094 |
| Email Notification Critical | 18 Jan, 2018 | US9884094 |
| Issue Notification Mailed Critical | 17 Jan, 2018 | US9884094 |
| Dispatch to FDC | 23 Dec, 2017 | US9884094 |
| Reverse Issue Fee | 21 Dec, 2017 | US9884094 |
Insulin Aspart; Insulin Degludec's Family Patents
